Monitor viral load prior to initiation or modification of treatment.
Monitor CD4 cell counts prior to initiation or with modification of ARV treatment and every 3-6 months; thereafter during at least the first 2 years of treatment.
Monitor hepatitis B screening.
Perform hepatitis C antibody testing prior to initiation or modification of ARV treatment.
Monitor ALT,AST, and total bilirubin, CBC with a differential, fasting blood glucose and lipid profile.
Monitor estimated creatinine clearance, serum creatinine, urine glucose, and urine protein prior to initiation and throughout treatment.